Founded in 2021, Rock BioMedical, Inc. (Rock Bio) is a biopharmaceutical company seeking to combine both active immunization (eg vaccines) and passive immunization (eg antibodies) for the eradication of diseases using our proprietary Glyco-Engineered Universal Vaccine (GEUV) platform. The company’s initial focus is on the development of next generation COVID-19 vaccine featuring the unique properties of our glycan-depleted SARS-CoV-2 spike protein (SMG), which is specifically designed to induce broad protection against immune evading variants. The company’s pipeline also includes novel therapeutic antibodies and universal flu vaccines developed using the same proprietary technology platform. Taken together, these vaccine and therapeutic antibody candidates can revolutionize the way common respiratory tract infections are managed in the future.
Rock Bio is founded on a set of core technologies in-licensed from Academia Sinica, Taiwan (ROC). The company has an R&D center located in the National Biotechnology Research Park in Nangang, Taipei and a U.S. subsidiary located in Boston, Massachusetts, USA, which manages Rock Bio’s global clinical development programs and international partnerships.
Private placement, seed round.
US subsidiary, Rock BioTherapeutics, Inc.
Taipei office launched at BioHub Taiwan.